AAV virions with decreased immunoreactivity and uses therefor
Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.
1. A polynucleotide encoding a mutated adeno-associated virus (AAV) capsid protein that when present in an AAV virion imparts decreased immunoreactivity to the virion as compared to the corresponding wild-type virion, wherein the mutated AAV capsid protein comprises a substitution of one or more of the amino acids occurring at a position corresponding to a position of the AAV-2 VP2 capsid selected from the group consisting of amino acid 126, 127, 128, 130, 315, 360, 361, 365, 375, 396, 407, 437, 568, and 571.
2. The polynucleotide of claim 1 , wherein the naturally occurring amino acid at the position is substituted with an alanine.
3. The polynucleotide of claim 1 , wherein the protein comprises a substitution of lysine for the naturally occurring amino acid at the position corresponding to the amino acid found at position 571 of AAV-2 VP2.
4. A recombinant AAV virion comprising a mutated adeno-associated virus (AAV) capsid protein that when present in an AAV virion imparts decreased immunoreactivity to the virion as compared to the corresponding wild-type virion, wherein the mutated AAV capsid protein comprises a substitution of one or more of the amino acids occurring at a position corresponding to a position of the AAV-2 VP2 capsid selected from the group consisting of amino acid 126, 127, 128, 130, 315, 360, 361, 365, 375, 396, 407, 437, 568, and 571.
5. The recombinant AAV virion of claim 4 , wherein the naturally occurring amino acid at the position is substituted with an alanine.
6. The recombinant AAV virion of claim 4 , wherein the protein comprises a substitution of lysine for the naturally occurring amino acid at the position corresponding to the amino acid found at position 571 of AAV-2 VP2.
7. The recombinant AAV virion of claim 4 , wherein said virion comprises a heterologous nucleic acid molecule encoding an antisense RNA or a ribozymes.
8. The recombinant AAV virion of claim 4 , wherein said virion comprises a heterologous nucleic acid molecule encoding a therapeutic protein operably linked to control elements capable of directing the in vivo transcription and translation of said protein.
9. The recombinant AAV virion of claim 5 , wherein said virion comprises a heterologous nucleic acid molecule encoding a therapeutic protein operably linked to control elements capable of directing the in vivo transcription and translation of said protein.
10. The recombinant AAV virion of claim 6 , wherein said virion comprises a heterologous nucleic acid molecule encoding a therapeutic protein operably linked to control elements capable of directing the in vivo transcription and translation of said protein.
11. A method of delivering a recombinant AAV virion to a cell or tissue of a vertebrate subject, said method comprising:
(a) providing a recombinant AAV virion according to claim 4 ;
(b) delivering said recombinant AAV virion to said cell or tissue, whereby said protein is expressed at a level that provides a therapeutic effect.
12. The method of claim 11 , wherein said cell or tissue is a muscle cell or tissue.
13. The method of claim 12 , wherein said muscle cell or tissue is derived from skeletal muscle.
14. The method of claim 11 , wherein said recombinant AAV virion is delivered into said cell or tissue in vivo.
15. The method of claim 14 , wherein said recombinant AAV virion is delivered by intramuscular injection.
16. The method of claim 11 , wherein said recombinant AAV virion is delivered into said cell or tissue in vitro.
17. The method of claim 11 , wherein said recombinant AAV virion is delivered into the bloodstream.
18. The method of claim 17 , wherein said recombinant AAV virion is delivered intravenously.
19. The method of claim 17 , wherein said recombinant AAV virion is delivered intraarterially.
20. The method of claim 11 , wherein said recombinant AAV virion is delivered to the liver.
21. The method of claim 11 , wherein said recombinant AAV virion is delivered to the brain.
22. The polynucleotide of claim 1 , wherein the protein comprises a substitution of histidine for the naturally occurring amino acid at the position corresponding to the amino acid found at position 360 of AAV-2 VP2.
23. The recombinant AAV virion of claim 4 , wherein the protein comprises a substitution of histidine for the naturally occurring amino acid at the position corresponding to the amino acid found at position 360 of AAV-2 VP2.
24. The recombinant AAV virion of claim 23 , wherein said virion comprises a heterologous nucleic acid molecule encoding a therapeutic protein operably linked to control elements capable of directing the in vivo transcription and translation of said protein.